Current approaches to diagnosis and treatment of invasive aspergillosis

American Journal of Respiratory and Critical Care Medicine

Volumn 173, Issue 7, 2006, Pages 707-717

  Segal, Brahm H ^a   Walsh, Thomas J ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b NONE

Author keywords

Aspergillus; Immunocompromised; Neutropenia; Transplant

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; COLONY STIMULATING FACTOR; ECHINOCANDIN; FLUCONAZOLE; GAMMA INTERFERON; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; PYRROLE DERIVATIVE; RAVUCONAZOLE; TOLL LIKE RECEPTOR; TRIAZOLE; VACCINE; VORICONAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIGEN DETECTION; ARTICLE; ASPERGILLOSIS; BONE MARROW TOXICITY; CHRONIC GRANULOMATOUS DISEASE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG MECHANISM; FUNGUS; GASTROINTESTINAL TOXICITY; GENOMICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE DEFICIENCY; IMMUNOMODULATION; IMMUNOTHERAPY; INNATE IMMUNITY; MORBIDITY; MORTALITY; NEPHROTOXICITY; NEUTROPENIA; NEUTROPHIL; ORGAN TRANSPLANTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; RISK ASSESSMENT; RISK FACTOR; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIFUNGAL AGENTS; ANTIGENS, FUNGAL; ASPERGILLOSIS; ASPERGILLUS; DIAGNOSIS, DIFFERENTIAL; DNA, FUNGAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; PROGNOSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33645302916     PISSN: 1073449X     EISSN: 1073449X     Source Type: Journal    
DOI: 10.1164/rccm.200505-727SO     Document Type: Article

References (118)

1. McNeil MM, Nash SL, Hajjeh RA, Phelan MA, Conn LA, Plikaytis BD, Warnock DW. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis 2001;33:641-647.
2. Denning DW. Introduction: the Aspergillus fumigatus genome database. Vol. 2003: The Institute for Genomic Research (TIGR). Available from: www.tigr.org/tdb/e2k1/afu1/intro.shtml (accessed 2003).
3. Gerson SL, Talbot GH, Hurwitz S, Strom BL, Lusk EJ, Cassileth PA. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med 1984;100:345-351.
4. Denning DW, Marinus A, Cohen J, Spence D, Herbrecht R, Pagano L, Kibbler C, Kcrmery V, Offner F, Cordonnier C, et al. An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group. J Infect 1998;37:173-180.
5. Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997;175:1459-1466.
6. Weinberger M, Elattar I, Marshall D, Steinberg SM, Redner RL, Young NS, Pizzo PA. Patterns of infection in patients with aplastic anemia and the emergence of Aspergillus as amajor cause of death. Medicine (Balt) 1992;71:24-43.
7. Baddley JW, Stroud TP, Salzman D, Pappas PG. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001;32:1319-1324.
8. Grow WB, Moreb JS, Roque D, Manion K, Leather H, Reddy V, Khan SA, Finiewicz KJ, Nguyen H, Clancy CJ, et al. Late onset of invasive aspergillus infection in bone marrow transplant patients at a university hospital. Bone Marrow Transplant 2002;29:15-19.
9. Jantunen E, Ruutu P, Niskanen L, Volin L, Parkkali T, Koukila-Kahkola P, Ruutu T. Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients. Bone Marrow Transplant 1997;19:801-808.
10. McWhinney PH, Kibbler CC, Hamon MD, Smith OP, Gandhi L, Berger LA,Walesby RK, Hoffbrand AV, Prentice HG. Progress in the diagnosis and management of aspergillosis in bone marrow transplantation: 13 years' experience. Clin Infect Dis 1993;17:397-404.
11. Yuen KY, Woo PC, Ip MS, Liang RH, Chiu EK, Siau H, Ho PL, Chen FF, Chan TK. Stage-specific manifestation of mold infections in bone marrow transplant recipients: risk factors and clinical significance of positive concentrated smears. Clin Infect Dis 1997;25:37-42.
12. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002;100:4358-4366.
13. Martino R, Subira M, Rovira M, Solano C, Vazquez L, Sanz GF, Urbano-Ispizua A, Brunet S, De la Camara R. Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br J Haematol 2002;116:475-482.
14. Shaukat A, Bakri F, Young P, Hahn T, Ball D, Baer MR, Wetzler M, Slack JL, Loud P, Czuczman M, et al. Invasive filamentous fungal infections in allogeneic hematopoietic stem cell transplant recipients after recovery from neutropenia: clinical, radiologic, and pathologic characteristics. Mycopathologia 2005;159:181-188.
15. Ng TT, Robson GD, Denning DW. Hydrocortisone-enhanced growth of Aspergillus spp.: implications for pathogenesis. Microbiol 1994;140:2475-2479.
16. Marty FM, Lee SJ, Fahey MM, Alyea EP, Soiffer RJ, Antin JH, Baden LR. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors for non-Candida invasive fungal infections in allogeneic hematopoietic transplant recipients: a cohort study. Blood 2003;102:2768-2776.
17. Patterson JE, Peters J, Calhoon JH, Levine S, Anzueto A, Al-Abdely H, Sanchez R, Patterson TF, Rech M, Jorgensen JH, et al. Investigation and control of aspergillosis and other filamentous fungal infections in solid organ transplant recipients. Transpl Infect Dis 2000;2:22-28.
18. Hadjiliadis D, Howell DN, Davis RD, Lawrence CM, Rea JB, Tapson VF, Perfect JR, Palmer SM. Anastomotic infections in lung transplant recipients. Ann Transplant 2000;5:13-19.
19. Westney GE, Kesten S, De Hoyos A, Chapparro C, Winton T, Maurer JR. Aspergillus infection in single and double lung transplant recipients. Transplantation 1996;61:915-919.
20. Hadjiliadis D, Sporn TA, Perfect JR, Tapson VF, Davis RD, Palmer SM. Outcome of lung transplantation in patients with mycetomas. Chest 2002;121:128-134.
21. Cahill BC, Hibbs JR, Savik K, Juni BA, Dosland BM, Edin-Stibbe C, Hertz MI. Aspergillus airway colonization and invasive disease after lung transplantation. Chest 1997;112:1160-1164.
22. Denning DW, Follansbee SE, Scolaro M, Norris S, Edelstein H, Stevens DA. Pulmonary aspergillosis in the acquired immunodeficiency syndrome. N Engl J Med 1991;324:654-662.
23. Denning DW, Lee JY, Hostetler JS, Pappas P, Kauffman CA, Dewsnup DH, Galgiani JN, Graybill JR, Sugar AM, Catanzaro A, et al. NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis. Am J Med 1994;97:135-144. [Published erratum appears in Am J Med 1994;97:497.]
24. Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996;23:608-615.
25. Holding KJ, Dworkin MS, Wan PC, Hanson DL, Klevens RM, Jones JL, Sullivan PS. Aspergillosis among people infected with human immunodeficiency virus: incidence and survival. Adult and adolescent spectrum of HIV Disease Project. Clin Infect Dis 2000;31:1253-1257.
26. Mylonakis E, Rich J, Skolnik PR, De Orchis DF, Flanigan T. Invasive Aspergillus sinusitis in patients with human immunodeficiency virus infection: report of 2 cases and review. Medicine (Baltimore) 1997;76:249-255.
27. Mylonakis E, Barlam TF, Flanigan T, Rich JD. Pulmonary aspergillosis and invasive disease in AIDS: review of 342 cases. Chest 1998;114:251-262.
28. Pursell KJ, Telzak EE, Armstrong D. Aspergillus species colonization and invasive disease in patients with AIDS. Clin Infect Dis 1992;14:141-148.
29. Mouy R, Veber F, Blanche S, Donadieu J, Brauner R, Levron JC, Griscelli C, Fischer A. Long-term itraconazole prophylaxis against Aspergillus infections in thirty-two patients with chronic granulomatous disease. J Pediatr 1994;125:998-1003.
30. Cohen MS, Isturiz RE, Malech HL, Root RK, Wilfert CM, Gutman L, Buckley RH. Fungal infection in chronic granulomatous disease: the importance of the phagocyte in defense against fungi. Am J Med 1981;71:59-66.
31. Segal BH, Holland SM. Invasive aspergillosis in chronic granulomatous disease. Available from: http://www.aspergillus.man.ac.uk (accessed 2003).
32. Almyroudis NG, Holland SM, Segal BH. Invasive aspergillosis in primary immunodeficiencies. Med Mycol Suppl 2005;43:S247-S259.
33. Winkelstein JA, Marino MC, Johnston RB Jr, Boyle J, Curnutte J, Gallin JI, Malech HL, Holland SM, Ochs H, Quie P, et al. Chronic granulomatous disease: report on a national registry of 368 patients. Medicine (Baltimore) 79:155-169.
34. Gallin JI, Alling DW, Malech HL, Wesley R, Koziol D, Marciano B, Eisenstein EM, Turner ML, DeCarlo ES, Starling JM, et al. Itraconazole prophylaxis for fungal infections in chronic granulomatous disease of childhood. N Engl J Med 2003;348:2416-2422.
35. Levine SJ. An approach to the diagnosis of pulmonary infections in immunosuppressed patients. Semin Respir Infect 1992;7:81-95.
36. Yu VL,Muder RR, Poorsattar A. Significance of isolation of Aspergillus from the respiratory tract in diagnosis of invasive pulmonary aspergillosis: results from a three- year prospective study. Am J Med 1986;81:249-254.
37. Greene R. The radiologic spectrum of pulmonary aspergillosis. Presented at Advances against Aspergillosis conference; September 9-11, 2004; San Francisco, CA.
38. Kuhlman JE, Fishman EK, Burch PA, Karp JE, Zerhouni EA, Siegelman SS. Invasive pulmonary aspergillosis in acute leukemia: the contribution of CT to early diagnosis and aggressive management. Chest 1987;92:95-99.
39. Caillot D, Casasnovas O, Bernard A, Couaillier JF, Durand C, Cuisenier B, Solary E, Piard F, Petrella T, Bonnin A, et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 1997;15:139-147.
40. Caillot D, Couaillier JF, Bernard A, Casasnovas O, Denning DW, Mannone L, Lopez J, Couillault G, Piard F, Vagner O, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 2001;19:253-259.
41. Bretagne S, Costa JM, Bart-Delabesse E, Dhedin N, Rieux C, Cordonnier C. Comparison of serum galactomannan antigen detection and competitive polymerase chain reaction for diagnosing invasive aspergillosis. Clin Infect Dis 1998;26:1407-1412.
42. Ascioglu S, Rex JH, de Pauw B, Bennett JE,Bille J, Crokaert F, Denning DW, Donnelly JP, Edwards JE, Erjavec Z, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002;34:7-14.
43. Wheat LJ. Rapid diagnosis of invasive aspergillosis by antigen detection. Transpl Infect Dis 2003;5:158-166.
44. Mennink-Kersten MA, Donnelly JP, Verweij PE. Detection of circulating galactomannan for the diagnosis and management of invasive asperillosis. Lancet Infect Dis 2004;4:349-357.
45. Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 2005;40:1762-1769.
46. Sulahian A, Touratier S, Ribaud P. False positive test for Aspergillus antigenemia related to concomitant administration of piperacillin and tazobactam. N Engl J Med 2003;349:2366-2367.
47. Maertens J, Van Eldere J, Verhaegen J, Verbeken E, Verschakelen J, Boogaerts M. Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients. J Infect Dis 2002;186:1297-1306.
48. Herbrecht R, Letscher-Bru V, Oprea C, Lioure B, Waller J, Campos F, Villard O, Liu KL, Natarajan-Ame S, Lutz P, et al. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol 2002;20:1898-1906.
49. Odabasi Z, Mattiuzzi G, Estey E, Kantarjian H, Saeki F, Ridge RJ, Ketchum PA, Finkelman MA, Rex JH, Ostrosky-Zeichner L. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004;39:199-205.
50. Ostrosky-Zeichner L, Alexander BD, Kett DH, Vazquez J, Pappas PG, Saeki F, Ketchum PA, Wingard J, Schiff R, Tamura H, et al. Multicenter clinical evaluation of the (1 → 3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005;41:654-659.
51. Pham AS, Tarrand JJ, May GS, Lee MS, Kontoyiannis DP, Han XY. Diagnosis of invasive mold infection by real-time quantitative PCR. Am J Clin Pathol 2003;119:38-44.
52. Ferns RB, Fletcher H, Bradley S, Mackinnon S, Hunt C, Tedder RS. The prospective evaluation of a nested polymerase chain reaction assay for the early detection of Aspergillus infection in patients with leukaemia or undergoing allograft treatment. Br J Haematol 2002;119:720-725.
53. Hebart H, Loffler J, Reitze H, Engel A, Schumacher U, Klingebiel T, Bader P, Bohme A, Martin H, Bunjes D, et al. Prospective screening by a panfungal polymerase chain reaction assay in patients at risk for fungal infections: implications for the management of febrile neutropenia. Br J Haematol 2000;111:635-640.
54. Buchheidt D, Baust C, Skladny H, Ritter J, Suedhoff T, Baldus M, Seifarth W, Leib-Moesch C, Hehlmann R. Detection of Aspergillus species in blood and bronchoalveolar lavage samples from immunocompromised patients by means of 2-step polymerase chain reaction: clinical results. Clin Infect Dis 2001;33:428-435.
55. Raad I, Hanna H, Huaringa A, Sumoza D, Hachem R, Albitar M. Diagnosis of invasive pulmonary aspergillosis using polymerase chain reaction-based detection of aspergillus in BAL. Chest 2002;121:1171-1176.
56. Kawazu M, Kanda Y, Goyama S, Takeshita M, Nannya Y, Niino M, Komeno Y, Nakamoto T, Kurokawa M, Tsujino S, et al. Rapid diagnosis of invasive pulmonary aspergillosis by quantitative polymerase chain reaction using bronchial lavage fluid. Am J Hematol 2003;72:27-30.
57. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-415.
58. Troke PF, Schwartz S, Ruhnke M, Ribaud P, Corey L, Driscoll T, Fatkenheuer G, Schuler U, Thiel E, Dodell B, et al. Voriconazole (VCR) therapy (Rx) in 86 patients (pts) with CNS aspergillosis (CNSA): a retrospective analysis. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2003.
59. Walsh TJ, Lutsar I, Driscoll T, Dupont B, Roden M, Ghahramani P, Hodges M, Groll AH, Perfect JR. Voriconazole in the treatment of aspergillosis, scedosporiosis, and other invasive fungal infections in children. Pediatr Infect Dis J 2002;21:240-248.
60. Walsh TJ, Petraitis V, Petraitiene R, Field-Ridley A, Sutton D, Ghannoum M, Sein T, Schaufele R, Peter J, Bacher J, et al. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B. J Infect Dis 2003;188:305-319.
61. Steinbach WJ, Benjamin DK, Jr., Kontoyiannis DP, Perfect JR, Lutsar I, Marr KA, Lionakis MS, Torres HA, Jafri H, Walsh TJ. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis 2004;39:192-198.
62. Kirkpatrick WR, Perea S, Coco BJ, Patterson TF. Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 2002;46:2564-2568.
63. Petraitis V, Petraitiene R, Sarafandi AA, Kelaher AM, Lyman CA, Casler HE, Sein T, Groll AH, Bacher J, Avila NA, et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis 2003;187:1834-1843.
64. Luque JC, Clemons KV, Stevens DA. Efficacy of micafungin alone or in combination against systemic murine aspergillosis. Antimicrob Agents Chemother 2003;47:1452-1455.
65. Chandrasekar PH, Cutright JL, Manavathu EK. Efficacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive aspergillosis. Clin Microbiol Infect 2004;10:925-928.
66. Sivak O, Bartlett K, Risovic V, Choo E, Marra F, Batty DS,Wasan KM. Assessing the antifungal activity and toxicity profile of amphotericin B lipid complex (ABLC; Abelcet) in combination with caspofungin in experimental systemic aspergillosis. J Pharm Sci 2004;93:1382-1389.
67. Graybill JR, Bocanegra R, Gonzalez GM, Najvar LK. Combination antifungal therapy of murine aspergillosis: liposomal amphotericin B and micafungin. J Antimicrob Chemother 2003;52:656-662.
68. Aliff TB, Maslak PG, Jurcic JG, Heaney ML, Cathcart KN, Sepkowitz KA, Weiss MA. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer 2003;97:1025-1032.
69. Kontoyiannis DP, Hachem R, Lewis RE, Rivero GA, Torres HA, Thornby J, Champlin R, Kantarjian H, Bodey GP, Raad II. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 2003;98:292-299.
70. Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004;39:797-802.
71. Raad I, Chapman S, Bradsher R, Morrison V, Goldman M, Graybill J, Perfect JR, Patterson T, Walsh T, Corcoran G, et al. Posaconazole (POS) salvage therapy for invasive fungal infections. Forty-fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC (M-669), 2004.
72. Segal BH, Barnhart LA, Anderson VL,Walsh TJ, Malech HL, Holland SM. Posaconazole as salvage therapy in patients with chronic granulomatous disease with invasive filamentous fungal infection. Clin Infect Dis 2005;40:1684-1688.
73. Offner F, Cordonnier C, Ljungman P, Prentice HG, Engelhard D, De Bacquer D, Meunier F, De Pauw B. Impact of previous aspergillosis on the outcome of bone marrow transplantation. Clin Infect Dis 1998;26:1098-1103.
74. Fukuda T, Boeckh M, Guthrie KA, Mattson DK, Owens S, Wald A, Sandmaier BM, Corey L, Storb RF, Marr KA. Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center. Biol Blood Marrow Transplant 2004;10:494-503.
75. Ozer H, Armitage JO, Bennett CL, Crawford J, Demetri GD, Pizzo PA, Schiffer CA, Smith TJ, Somlo G, Wade JC, et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 2000;18:3558-3585.
76. Giles FJ. Monocyte-macrophages, granulocyte-macrophage colony-stimulating factor, and prolonged survival among patients with acute myeloid leukemia and stem cell transplants. Clin Infect Dis 1998;26:1282-1289.
77. Rowe JM, Andersen JW, Mazza JJ, Bennett JM, Paietta E, Hayes FA, Oette D, Cassileth PA, Stadtmauer EA, Wiernik PH. A randomized placebo-controlled phase III study of granulocyte- macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood 1995;86:457-462.
78. Roilides E, Uhlig K, Venzon D, Pizzo PA, Walsh TJ. Enhancement of oxidative response and damage caused by human neutrophils to Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect Immun 1993;61:1185-1193.
79. Roilides E, Holmes A, Blake C, Venzon D, Pizzo PA, Walsh TJ. Antifungal activity of elutriated human monocytes against Aspergillus fumigatus hyphae: enhancement by granulocyte-macrophage colonystimulating factor and interferon-gamma. J Infect Dis 1994;170:894-899.
80. Roilides E, Sein T, Holmes A, Chanock S, Blake C, Pizzo PA, Walsh TJ. Effects of macrophage colony-stimulating factor on antifungal activity of mononuclear phagocytes against Aspergillus fumigatus. J Infect Dis 1995;172:1028-1034.
81. Roilides E, Holmes A, Blake C, Pizzo PA,Walsh TJ. Effects of granulocyte colony-stimulating factor and interferon-gamma on antifungal activity of human polymorphonuclear neutrophils against pseudohyphae of different medically important Candida species. J Leukoc Biol 1995;57:651-656.
82. Nemunaitis J. Use of macrophage colony-stimulating factor in the treatment of fungal infections. Clin Infect Dis 1998;26:1279-1281.
83. Bensinger WI, Price TH, Dale DC, Appelbaum FR, Clift R, Lilleby K, Williams B, Storb R, Thomas ED, Buckner CD. The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis. Blood 1993;81:1883-1888.
84. Price TH, Bowden RA, Boeckh M, Bux J, Nelson K, Liles WC, Dale DC. Phase I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infections in hematopoeitic stem cell transplantation. Blood 2000;95:3302-3309.
85. Nichols WG, Price T, Boeckh M. Cytomegalovirus infections in cancer patients receiving granulocyte transfusions. Blood 2002;99:3483-3484.
86. Winn RM, Gil-Lamaignere C, Roilides E, Simitsopoulou M, Lyman CA, Maloukou A, Walsh TJ. Selective effects of interleukin (IL)-15 on antifungal activity and IL-8 release by polymorphonuclear leukocytes in response to hyphae of Aspergillus species. J Infect Dis 2003;188:585-590.
87. Vazquez N,Walsh TJ, Friedman D, Chanock SJ, Lyman CA. Interleukin-15 augments superoxide production and microbicidal activity of human monocytes against Candida albicans. Infect Immun 1998;66:145-150.
88. Mehrad B, Strieter RM, Moore TA, Tsai WC, Lira SA, Standiford TJ. CXC chemokine receptor-2 ligands are necessary components of neutrophil-mediated host defense in invasive pulmonary aspergillosis. J Immunol 1999;163:6086-6094.
89. Stevens DA. Combination immunotherapy and antifungal chemotherapy. Clin Infect Dis 1998;26:1266-1269.
90. Segal BH, Holland SM. Interferon-gamma in infectious diseases. In: Kawakami K, Stevens DA, editors. Immunomodulators as promising therapeutic agents against infectious diseases. Kerala, India: Research Signpost; 2004. pp. 23-54.
91. Roilides E, Uhlig K, Venzon D, Pizzo PA, Walsh TJ. Prevention of corticosteroid-induced suppression of human polymorphonuclear leukocyte-induced damage of Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect Immun 1993;61:4870-4877.
92. Rex JH, Bennett JE, Gallin JI, Malech HL, DeCarlo ES, Melnick DA. In vivo interferon-gamma therapy augments the in vitro ability of chronic granulomatous disease neutrophils to damage Aspergillus hyphae. J Infect Dis 1991;163:849-852.
93. Del Sero G, Mencacci A, Cenci E, d'Ostiani CF, Montagnoli C, Bacci A, Mosci P, Kopf M, Romani L. Antifungal type 1 responses are upregulated in IL-10-deficient mice. Microbes Infect 1999;1:1169-1180.
94. Cenci E, Mencacci A, Del Sero G, Bacci A, Montagnoli C, d'Ostiani CF, Mosci P, Bachmann M, Bistoni F, Kopf M, et al. Interleukin-4 causes susceptibility to invasive pulmonary aspergillosis through suppression of protective type I responses. J Infect Dis 1999;180:1957-1968.
95. Cenci E, Mencacci A, Fe d'Ostiani C, Del Sero G, Mosci P, Montagnoli C, Bacci A, Romani L. Cytokine- and T helper-dependent lung mucosal immunity in mice with invasive pulmonary aspergillosis. J Infect Dis 1998;178:1750-1760.
96. Cenci E, Perito S, Enssle KH, Mosci P, Latge JP, Romani L, Bistoni F. Th1 and Th2 cytokines in mice with invasive aspergillosis. Infect Immun 1997;65:564-570.
97. Nagai H, Guo J, Choi H, Kurup V. Interferon-gamma and tumor necrosis factor-alpha protect mice from invasive aspergillosis. J Infect Dis 1995;172:1554-1560.
98. International Chronic Granulomatous Disease Cooperative Study Group. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease: the International Chronic Granulomatous Disease Cooperative Study Group. N Engl J Med 1991;324:509-516.
99. Fleming RV, Anaissie EJ, Kantarjian HM, Savary C, Rex JH. Safety of interferon-gamma plus G-CSF in cancer patients with refractory fungal infections: a pilot study. Thirty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 1997.
100. Safdar A, Rodriguez G, Ohmagari N, Kontoyiannis DP, Rolston KV, Raad II, Champlin RE. The safety of interferon-gamma-1b for invasive fungal infections after hematopoietic stem cell transplantation. Cancer 2005;103:731-739.
101. Netea MG, Warris A, Van der Meer JW, Fenton MJ, Verver-Janssen TJ, Jacobs LE, Andresen T, Verweij PE, Kullberg BJ. Aspergillus fumigatus evades immune recognition during germination through loss of toll-like receptor-4-mediated signal transduction. J Infect Dis 2003;188:320-326.
102. Meier A, Kirschning CJ, Nikolaus T, Wagner H, Heesemann J, Ebel F. Toll-like receptor (TLR) 2 and TLR4 are essential for Aspergillus-induced activation of murine macrophages. Cell Microbiol 2003;5:561-570.
103. Mambula SS, Sau K, Henneke P, Golenbock DT, Levitz SM. Toll-like receptor (TLR) signaling in response to Aspergillus fumigatus. J Biol Chem 2002;277:39320-39326.
104. Bozza S, Gaziano R, Lipford GB, Montagnoli C, Bacci A, Di Francesco P, Kurup VP, Wagner H, Romani L. Vaccination of mice against invasive aspergillosis with recombinant Aspergillus proteins and CpG oligodeoxynucleotides as adjuvants. Microbes Infect 2002;4:1281-1290.
105. Romani L, Bistoni F, Gaziano R, Bozza S, Montagnoli C, Perruccio K, Pitzurra L, Bellocchio S, Velardi A, Rasi G, et al. Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood 2004;103:4232-4329.
106. Bellocchio S, Moretti S, Perruccio K, et al. TLRs govern neutrophil activity in aspergillosis. J Immunol 2004;173:7406-7415.
107. Bellocchio S, Gaziano R, Bozza S, Rossi G, Montagnoli C, Perruccio K, Calvitti M, Pitzurra L, Romani L. Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting Toll-like receptor signalling from TLR-2 to TLR-4. J Antimicrob Chemother 2005;55:214-222.
108. Garlanda C, Hirsch E, Bozza S, Salustri A, De Acetis M, Nota R, Maccagno A, Riva F, Bottazzi B, Peri G, et al. Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response. Nature 2002;420:182-186.
109. Gaziano R, Bozza S, Bellocchio S, Perruccio K, Montagnoli C, Pitzurra L, Salvatori G, De Santis R, Carminati P, Mantovani A, et al. Anti-Aspergillus fumigatus efficacy of pentraxin 3 alone and in combination with antifungals. Antimicrob Agents Chemother 2004;48:4414-4421.
110. Romani L. Immunity to fungal infections. Nat Rev Immunol 2004;4:1-23.
111. Stevens DA. Vaccinate against aspergillosis! A call to arms of the immune system. Clin Infect Dis 2004;38:1131-1136.
112. Cenci E, Mencacci A, Bacci A, Bistoni F, Kurup VP, Romani L. T cell vaccination in mice with invasive pulmonary aspergillosis. J Immunol 2000;165:381-388.
113. Torosantucci A, Bromuro C, Chiani P, De Bernardis F, Berti F, Galli C, Norelli F, Bellucci C, Polonelli L, Costantino P, et al. Anovel glycoconjugate vaccine against fungal pathogens. J Exp Med 2005;202:597-606.
114. Bozza S, Perruccio K, Montagnoli C, Gaziano R, Bellocchio S, Burchielli E, Nkwanyuo G, Pitzurra L, Velardi A, Romani L. A dendritic cell vaccine against invasive aspergillosis in allogeneic hematopoietic transplantation. Blood 2003;5:5.
115. Perruccio K, Bozza S, Montagnoli C, Bellocchio S, Aversa F, Martelli M, Bistoni F, Velardi A, Romani L. Prospects for dendritic cell vaccination against fungal infections in hematopoietic transplantation. Blood Cells Mol Dis 2004;33:248-255.
116. Bozza S, Montagnoli C, Gaziano R, Rossi G, Nkwanyuo G, Bellocchio S, Romani L. Dendritic cell-based vaccination against opportunistic fungi. Vaccine 2004;22:857-864.
117. Romani L, Montagnoli C, Bozza S, Perruccio K, Spreca A, Allavena P, Verbeek S, Calderone RA, Bistoni F, Puccetti P. The exploitation of distinct recognition receptors in dendritic cells determines the full range of host immune relationships with Candida albicans. Int Immunol 2004;16:149-161.
118. Jiang B, Bussey H, Roemer T. Novel strategies in antifungal lead discovery. Curr Opin Microbiol 2002;5:466-471.